These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 10146934)

  • 41. Pharmaceuticals for developing countries: an interface of science, technology, and public policy.
    Simon HJ
    Pharos Alpha Omega Alpha Honor Med Soc; 1981; 44(2):9-15. PubMed ID: 12085902
    [No Abstract]   [Full Text] [Related]  

  • 42. The Australian National Medicinal Drug Policy.
    Sansom L
    J Qual Clin Pract; 1999 Mar; 19(1):31-5. PubMed ID: 10096722
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Process analytical technology in the pharmaceutical industry: a toolkit for continuous improvement.
    Scott B; Wilcock A
    PDA J Pharm Sci Technol; 2006; 60(1):17-53. PubMed ID: 17089677
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The evolution of Taiwan's National Health Insurance drug reimbursement scheme.
    Hsu JC; Lu CY
    Daru; 2015 Feb; 23(1):15. PubMed ID: 25889754
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
    Castillo-Laborde C; Silva-Illanes N
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PDA Points to Consider: Technical Product Lifecycle Management. Pharmaceutical Quality System Effectiveness for Managing Post-approval Changes.
    ; Ramnarine E; Busse U; Colao M; Edwards J; O'Donnell K; Jornitz M; Munk M; Seymour M; Simianu M; Skeens L; Vinther A
    PDA J Pharm Sci Technol; 2017; 71(3):252-258. PubMed ID: 28196929
    [No Abstract]   [Full Text] [Related]  

  • 47. Quality use of medicines in the community: the Australian experience.
    Smith AJ; McGettigan P
    Br J Clin Pharmacol; 2000 Dec; 50(6):515-9. PubMed ID: 11136290
    [No Abstract]   [Full Text] [Related]  

  • 48. Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang?
    Drummond M
    Pharmacoeconomics; 1992; 1(Suppl 1):61-9. PubMed ID: 10146934
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan.
    Thatte U; Hussain S; de Rosas-Valera M; Malik MA
    Value Health; 2009; 12 Suppl 3():S18-25. PubMed ID: 20586975
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures.
    Grabowski H
    Pharmacoeconomics; 2004; 22(2 Suppl 2):15-24. PubMed ID: 15660474
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan.
    Jirawattanapisal T; Kingkaew P; Lee TJ; Yang MC
    Value Health; 2009; 12 Suppl 3():S4-11. PubMed ID: 20586980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 3.